BCYP News and Press, SAB Biotherapeutics Inc Com From 01/05/23

SIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors,&...

Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nas...

Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics Sets Stage for Public Debut of SAB, Whose Unique Immunotherapy Platform Produces Targeted, High-Potency Fully-Human Polyclonal Antibodies Without the Need for Human Donors PR New...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on We...

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced that the first patient has been dosed with SA...

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief fin...

Advancement to Phase 3 is major milestone for SAB’s unique DiversitAb ™ immunotherapy platform that produces fully-human polyclonal antibodies without human donors Both doses of SAB-185 tested in Phase 2 met pre-defined efficacy goal at interim analysis ...

Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics Registration Statement on Form S-4 Has Been Declared Effective by Securities and Exchange Commission Stockholder Vote Scheduled for October 20, 202...

$200 million total awarded to date for DiversitAb™ Rapid Response Antibody Program including Stage 4 COVID-19 Pandemic Response Expanded contract scope includes commercial manufacturing and clinical development through licensure for SAB-185 for the treatment of COVID-19...